Clinical Trials
Explore actively recruiting trials across hepatology and gastroenterology in the West of Scotland.
Current Trials
| Trial | Summary | Key inclusion | Key exclusion | Contact |
|---|---|---|---|---|
| Phase 2 placebo-controlled trial assessing mitoQ therapy for active ulcerative colitis. | Active UC (Mayo ≥6 with endoscopy ≥2), Age 16 years and above, stable background UC therapy allowed. | Severe or fulminant colitis, >2 advanced therapies in 2 years, UC limited to proctitis, PSC, pregnancy. | marvel.trial@ed.ac.uk | |
One-IBD | Registry capturing longitudinal data across IBD phenotypes and matched healthy controls. | Age 16 years and above with clinician-verified CD/UC/IBD-U or healthy controls linked to NHS GG&C or Lanarkshire data. | Unable to provide informed consent. | one-ibd@glasgow.ac.uk |
| Prospective study tracking mucosal healing markers in active Crohn's disease and ulcerative colitis. | Age 16 years and above with active IBD plus biomarker/endoscopic evidence within 6 weeks; endoscopy suitable for healing assessment. | Acute severe disease (Truelove & Witts), toxic megacolon, significant obstruction, abscess, or fistula. | ibdmusicstudy@ed.ac.uk | |
GI-DAMPs | Biomarker study comparing innate immune activation across IBD, symptomatic controls, and healthy volunteers. | Groups 1 & 2: Age 16-80 years attending for GI assessment; Group 3: healthy volunteers Age 16-80 years without GI symptoms. | Outside 16-80 age range, coagulation risk for biopsies, or language barriers preventing consent. | gidamps_contact@example.com |
ACESO | Upadacitinib Co-therapy with Corticosteroids in Early Acute Severe Ulcerative Colitis. Phase 3 randomised placebo-controlled trial. | Age 18-65 years with suspected/confirmed ASUC (MTWSI ≥11) requiring IV steroids; prior UC therapies incl. biologics/JAKs allowed with appropriate washouts. | Infective colitis, pregnancy, toxic megacolon; strong CYP3A4 inhibitors/inducers; cytopenias or renal/hepatic impairment; VTE without anticoagulation; recent malignancy; other JAK <4 wks; prior upadacitinib; live vaccines; TB/HBV/HCV; CTIMP participation. | aceso@example.com |
Abbvie M25-540 | Risankizumab Versus Vedolizumab for Subjects with Ulcerative Colitis Naïve to Targeted Therapies. | Adults 18-80 with active moderate UC (mMS 5-9, endoscopic 2-3), documented ≥3 months, and intolerance/inadequate response to conventional UC therapies. | Prior targeted UC therapies, recent systemic/rectal steroids, significant GI complications or infections, severe uncontrolled comorbidities, or lymphoproliferative disease history. | example@example.com |
VICTRIVA | Vedolizumab + Upadacitinib combination therapy for the treatment of patients with active Crohn's disease | Adults 18-65 with moderate to severe Crohn's disease (CDAI 220-450, SES-CD >=4/6) who have failed or were intolerant to standard therapies and meet study contraceptive requirements. | Exclude other IBD phenotypes, serious or chronic infections (including TB), high-risk comorbidities, prior vedolizumab/upadacitinib failure, or conflicted recent immunosuppressive/biologic use. | example@example.com |
Abbvie M24-885 | A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderate to Severe Crohn's Disease | Adults 18-75 with Crohn's disease (CDAI >=220, SES-CD >=4/6) weighing >=40 kg, able to consent, and previously intolerant or refractory to steroids, immunomodulators, or targeted biologics/small molecules. | Exclude abnormal safety labs, recent major surgery, significant infections (HBV/HCV/HIV/TB), high-risk comorbidities or CD complications, recent biologic/small-molecule exposure, unstable concomitant therapy, or recent substance abuse. | example@example.com |
B-SUPREME | A Randomized, Double-Blind, Active-Controlled Multicenter Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared with Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult Subjects with Chronic Hepatitis B Virus Infection | Adults 18-65 with chronic HBV (HBsAg ≥100 IU/mL, HBV DNA ≥20,000 IU/mL, ALT ≤8×ULN) who are treatment-naïve or have completed required washout and meet contraception requirements. | Cirrhosis or significant fibrosis, coinfections (HAV, HCV, HDV, HEV, HIV), clinically significant comorbidities, abnormal labs, recent investigational or prohibited therapies, or other high-risk factors per investigator. | example@example.com |
OPERA | Optimising Primary Therapy in Primary Biliary Cholangitis | Adults with recent (<6 months) primary biliary cholangitis, persistent alkaline phosphatase elevation, minimal prior UDCA exposure, and high predicted non-response risk to UDCA alone. | Contraindications to obeticholic acid, cirrhosis or biliary obstruction indicators, prior obeticholic acid use, high alcohol intake, pregnancy/breastfeeding, overlapping liver disease, or prior transplant. | example@example.com |
UCAB-CT-05 | A randomised, double-blind, placebo-controlled, two-part study to evaluate the pharmacokinetics, safety and tolerability, and preliminary efficacy of two dose levels of golexanolone in subjects with primary biliary cholangitis, fatigue, and cognitive dysfunction. | Adults ≥18 with PBC meeting ≥2 diagnostic criteria, PBC-40 fatigue ≥29 and cognition ≥16, on stable standard-of-care therapy with appropriate contraception and informed consent. | Exclude advanced liver disease, significant comorbidities or contraindicated therapies, uncontrolled thyroid or immune disorders, pregnancy/nursing, and other factors compromising safety or compliance. | example@example.com |
FATE-CD | A prospective cohort observational study investigating the role of fibrosis activity in Crohn's disease | Adults 18-90 with Crohn's disease involving the ileum; cohorts include surgical ileal strictures, non-stricturing ileal CD, age/sex-matched healthy controls, and new-diagnosis ileal CD starting anti-TNF; prior surgery allowed if recurrent ileal stricture on MRE; no stricture length limit. | Unable to consent; claustrophobia or unable to tolerate supine PET/MRI or PET/CT; eGFR <30 mL/min/1.73m²; pregnancy or breastfeeding; contrast allergy; MRI contraindication; significant mental health impairment; colonic-only disease; contraindication/allergy to buscopan. | fatecd@example.com |
PROMISE | A prospective faecal microbiota tranSplantation trial to improve outcomes in patients with cirrhosis | Age ≥18 with ALD/MASLD/MetALD cirrhosis (clinical/radiologic/histologic), MELD 8-16, alcohol-related cirrhosis ≤20 g/day, able to consent. | Significant food allergy; pregnancy/breastfeeding; recent decompensation (bleeding/infection/HE/SBP/ACLF ≤14 days); alcohol >20 g/day; prior liver transplant; IBD/coeliac or GI surgery altering microbiome; active malignancy; life expectancy <6 months or transplant-listed; HIV/HBV/HCV (unless undetectable); antibiotics/probiotics ≤7 days; swallowing disorder; recent investigational product ≤4 months. | promise@example.com |
STARLIGHT | A study to investigate the safety and efficacy of GSK4532990 compared with placebo in adult participants aged 18 to 65 years with alcohol-related liver disease. | Adults 18-65 with alcohol-related or metabolic-associated ALD (per investigator), able to consent/comply; women not pregnant/breastfeeding with highly effective contraception; stable dosing (≥3 months) of specified background agents permitted (e.g., GLP‑1/GIP, PPAR, SGLT2, THR‑β, FXR, FASN, FGF21, Vitamin E). | Alcohol abstinence ≥4 months; organ failure or decompensation/high MELD; low fibrosis markers (FibroScan LSM <15 kPa or ELF <9.8); lab/ECG safety thresholds (AST <ULN or AST/ALT ≥250, ALP ≥250, platelets <60×10^9/L, INR >2.3, albumin <2.8 g/dL); renal impairment/eGFR <75; HBV/HCV/HIV or other primary liver diseases; active infection; uncontrolled HTN, BMI >35, HbA1c ≥9.5; significant cardiac/renal disease, malignancy, recent major surgery or investigational therapy; pregnancy/breastfeeding; hypersensitivity to study drug; contraindications to MRE/biopsy; high psychosocial risk. | starlight@example.com |
Asp-PSC | Effect of Aspirin on Reducing Cancer & Improving Outcomes in Primary Sclerosing Cholangitis | Adults ≥18 with established large duct PSC and concomitant colonic IBD; ≥1 year post-PSC; stable UDCA ≤20 mg/kg/day for ≥12 weeks; recent colonoscopy; recent liver imaging per cirrhosis status. | Secondary sclerosing cholangitis/other liver diseases; prior CRC/CCA/gallbladder cancer; liver transplant or listed; prior colonic resection/ostomy; alcohol >14 units/week; current aspirin/NSAIDs/antiplatelet/anticoagulant use or recent CTIMP; history of GI bleed, CHF, or G6PD deficiency; Child-Pugh B/C; untreated thyroid disease; hereditary cancer risk; recent VZV vaccine; aspirin allergy or NSAID-induced asthma; bleeding disorders; peptic ulcer; gout; severe renal impairment; methotrexate >15 mg/week; SSRI use. | asp-psc@contact.com |
React-AVB | Randomised controlled trial of EArly transjugular intrahepatiC porTosystemic stent-shunt in Acute Variceal Bleeding | Adults ≥18 with cirrhosis, acute variceal bleed controlled after initial endoscopic therapy, and Child-Pugh 7-13. | Uncontrolled bleeding, prior portosystemic shunt/TIPSS or occlusive portal vein thrombosis, active cancer affecting 1-year survival, recurrent encephalopathy, pregnancy/lactation, or refractory heart failure/sepsis. | react-avb@example.com |
BOOST | β-hydroxy-β-methylbutyrate (HMB) supplementationto improve functional status in people with advanced liver cirrhosis | Adults 18-85 with advanced cirrhosis (Child-Pugh ≥7) and recent portal hypertension, with cirrhosis confirmed clinically/radiologically/histologically or elastography >15 kPa; able to consent or via representative. | Prognosis <6 months, advanced HCC, HMB use within 4 weeks, unable to complete Liver Frailty Index, liver transplant recipient/listed/under assessment, interventional trial in last 4 weeks, or poor engagement per PI. | boost@example.com |
ICONIC-CD | Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease | Adults ≥18 with moderately-severely active Crohn's disease: CDAI 220-450 plus central SES-CD ≥6 (≥4 if isolated ileal) with ulceration; diagnosis ≥12 weeks; screening labs within limits; prior inadequate response/intolerance to conventional or advanced CD therapy; on stable or appropriately washed-out background meds; meets consent and contraception requirements. | CD complications likely requiring surgery (symptomatic strictures, short gut), stoma/ostomy, undrained abscess or planned major surgery; history of dysplasia/uncleared polyps or non-CD colitides; active/latent TB or significant/recent infections; uncontrolled systemic comorbidities or recent malignancy/lymphoproliferative disease; prior IL-23p19/IL-23R exposure; recent prohibited biologics/JAKs/immunosuppressants/live vaccines; HIV/HBV/HCV positivity; or other factors compromising safety/compliance. | iconic@example.com |
NASH | Case-control Study Evaluating Biomarkers and Genetic Factors Associated with the Development of Non-alcoholic Steatohepatitis (NASH) and Alcoholic steatohepatitis (ASH). | Patients over 18 years old, have a clinical diagnosis of NAFLD or ALD (or no liver disease for controls), and report alcohol consumption above UK recommended limits for the ALD group. | Patients with other diagnosed liver diseases, suspected other causes of liver injury, hazardous alcohol consumption (except for the ALD group), or inability to provide informed consent are excluded. | nash@example.com |
VOCAL2 | Using volatile organic markers for monitoring cirrhosis and detecting primary liver tumours. | Adults ≥18 with confirmed HCC, CCA, cirrhosis, PSC, or non-specific GI symptoms with normal liver (healthy controls). | Active infection or immunosuppressive meds in last 8 weeks, history of other cancer in last 5 years, prior liver resection, prior chemo/radiotherapy/surgery for liver cancer, comorbidities preventing breath collection, pregnancy, unable to provide informed consent. | vocal2@example.com |
EMERALD | Open-label phase 1/2 multicentre study of RTX001 autologous macrophages in patients with decompensated liver cirrhosis | Adults 18-75 with liver cirrhosis (ALD/MASLD/Met-ALD), recent major hepatic decompensation, MELD 12-20, PEth <200 ng/ml, no contraindications to filgrastim/leukapheresis. | Liver cirrhosis due to viral/autoimmune/cholestatic disorders, acute liver disease, current organ failure, splenomegaly ≥16 cm, thrombocytopenia <50×10^9/L, co-morbidities (transplant, ACLF, active sepsis, HIV/syphilis/HTLV-1, PE, HCC/active malignancy, portal vein thrombosis, hepatic hydrothorax, chronic renal impairment/AKI, heart failure, porto-pulmonary hypertension, severe lung disease, hepatopulmonary syndrome, multiple albumin infusions, untreated psychiatric disease, TIPS), intercurrent illness, immunomodulators/immunosuppressants, prior gene/cell therapy, live attenuated vaccines, investigational product, hypersensitivity to DMSO, unlikely to comply, pregnancy/breastfeeding, alcohol misuse, non-medically supervised drug abuse. | emerald@example.com |